Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8764228 | 0.84 | ALDH1A1 (0.35) | GAAHTTMAPTRAB9ANPC1 | |
| SCHEMBL29876843 | 0.78 | GAA (0.50) | GAAHTTMAPTRAB9ANPC1 | |
| SCHEMBL1939410 | 0.78 | GAA (0.50) | GAAHTTMAPTRAB9ANPC1 | |
| SCHEMBL14411538 | 0.78 | GAA (0.46) | GAAHTTMAPTRAB9ANPC1 | |
| SCHEMBL22663499 | 0.78 | TRPA1 (0.46) | GAAHTTMAPTRAB9ANPC1 | |
| SCHEMBL1943622 | 0.74 | — | — | |
| SCHEMBL1268881 | 0.73 | ALDH1A1 (0.47) | HTTMAPTRAB9AKDM4ELMNA | |
| SCHEMBL3166136 | 0.73 | SMN1; SMN2 (0.45) | GAAHTTMAPTRAB9ANPC1 | |
| SCHEMBL6304709 | 0.73 | SIGMAR1 (0.36) | — | |
| SCHEMBL11289154 | 0.73 | MAPT (0.48) | GAAHTTMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229450-A1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | SYNGENTA LIMITED (GB) | 2006-10-12 | — | — | US | claimed |
| US-7084272-B2 | Process for the preparation of azoxystrobin and analogues thereof | SYNGENTA LIMITED (GB) | 2006-08-01 | — | — | US | claimed |
| US-20040242607-A1 | Process for the preparation of azoxystrobin and analogues thereof | SYNGENTA LIMITED (GB) | 2004-12-02 | — | — | US | claimed |
| EP-1399427-B1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | SYNGENTA LTD (GB) | 2004-11-03 | — | — | EP | claimed |
| EP-1399427-A1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | Syngenta Limited (GB) | 2004-03-24 | — | — | EP | claimed |
| WO-2002100837-A1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | SYNGENTA LIMITED (GB) | 2002-12-19 | — | — | WO | claimed |
| US-7244737-B2 | Process for the preparation of azoxystrobin and analogues thereof | SYNGENTA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-7244737-B2 | Process for the preparation of azoxystrobin and analogues thereof | SYNGENTA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-20060229450-A1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | SYNGENTA LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
| US-20060229450-A1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | SYNGENTA LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
| US-7084272-B2 | Process for the preparation of azoxystrobin and analogues thereof | SYNGENTA LIMITED (GB) | 2006-08-01 | — | — | US | disclosed |
| US-7084272-B2 | Process for the preparation of azoxystrobin and analogues thereof | SYNGENTA LIMITED (GB) | 2006-08-01 | — | — | US | disclosed |
| CN-1259313-C | Process for preparation of azoxystrobin and analogues thereof | SYNGENTA LTD (GB) | 2006-06-14 | — | — | CN | disclosed |
| EP-1399427-B1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | SYNGENTA LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| EP-1399427-B1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | SYNGENTA LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| CN-1511144-A | Process for preparation of azoxystrobin and analogues thereof | — | 2004-07-07 | — | — | CN | disclosed |
| EP-1399427-A1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | Syngenta Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| EP-1399427-A1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | Syngenta Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002100837-A1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | SYNGENTA LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100837-A1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | SYNGENTA LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242607-A1 | Process for the preparation of azoxystrobin and analogues thereof | CYP4F2, PAH, FBL | GAA 1862/4885HTT 1681/4885MAPT 4786/4885 |
| US-20060229450-A1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | CYP4F2, CYP4F11, CYP4B1 | GAA 1224/4885HTT 2722/4885MAPT 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.